Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Research

Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis

Authors: Jianpeng Li, Jinlong Cao, Pan Li, Zhiqiang Yao, Ran Deng, Lijun Ying, Junqiang Tian

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Bladder cancer (BC) is a common malignancy neoplasm diagnosed in advanced stages in most cases. It is crucial to screen ideal biomarkers and construct a more accurate prognostic model than conventional clinical parameters. The aim of this research was to develop and validate an mRNA-based signature for predicting the prognosis of patients with bladder cancer.

Methods

The RNA-seq data was downloaded from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) were screened in three datasets, and prognostic genes were identified from the training set of TCGA dataset. The common genes between DEGs and prognostic genes were narrowed down to six genes via Least Absolute Shrinkage and Selection Operator (LASSO) regression, and stepwise multivariate Cox regression. Then the gene-based risk score was calculated via Cox coefficient. Time-dependent receiver operating characteristic (ROC) and Kaplan-Meier (KM) survival analysis were used to assess the prognostic power of risk score. Multivariate Cox regression analysis was applied to construct a nomogram. Decision curve analysis (DCA), calibration curves, and time-dependent ROC were performed to assess the nomogram. Finally, functional enrichment of candidate genes was conducted to explore the potential biological pathways of candidate genes.

Results

SORBS2, GPC2, SETBP1, FGF11, APOL1, and H1–2 were screened to be correlated with the prognosis of BC patients. A nomogram was constructed based on the risk score, pathological stage, and age. Then, the calibration plots for the 1-, 3-, 5-year OS were predicted well in entire TCGA-BLCA patients. Decision curve analysis (DCA) indicated that the clinical value of the nomogram was higher than the stage model and TNM model in predicting overall survival analysis. The time-dependent ROC curves indicated that the nomogram had higher predictive accuracy than the stage model and risk score model. The AUC of nomogram time-dependent ROC was 0.763, 0.805, and 0.806 for 1-year, 3-year, and 5-year, respectively. Functional enrichment analysis of candidate genes suggested several pathways and mechanisms related to cancer.

Conclusions

In this research, we developed an mRNA-based signature that incorporated clinical prognostic parameters to predict BC patient prognosis well, which may provide a novel prognosis assessment tool for clinical practice and explore several potential novel biomarkers related to the prognosis of patients with BC.
Appendix
Available only for authorised users
Literature
10.
go back to reference Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, et al. Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Urol Oncol. 2019;37(11):810 e817–5.CrossRef Krafft U, Tschirdewahn S, Hess J, Harke NN, Hadaschik B, Olah C, et al. Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. Urol Oncol. 2019;37(11):810 e817–5.CrossRef
17.
go back to reference Yang W, Han J, Ma J, Feng Y, Hou Q, Wang Z, et al. Prediction of key gene function in spinal muscular atrophy using guilt by association method based on network and gene ontology. Exp Ther Med. 2019;17(4):2561–6.PubMedPubMedCentral Yang W, Han J, Ma J, Feng Y, Hou Q, Wang Z, et al. Prediction of key gene function in spinal muscular atrophy using guilt by association method based on network and gene ontology. Exp Ther Med. 2019;17(4):2561–6.PubMedPubMedCentral
23.
go back to reference Chen H. VennDiagram: generate high-resolution Venn and Euler plots. R package version 1620; 2018. Chen H. VennDiagram: generate high-resolution Venn and Euler plots. R package version 1620; 2018.
24.
go back to reference Therneau TM. A Package for Survival Analysis in S. version 238; 2015. Therneau TM. A Package for Survival Analysis in S. version 238; 2015.
28.
go back to reference Frank EHJ. rms: Regression Modeling Strategies. R package version 51–4; 2019. Frank EHJ. rms: Regression Modeling Strategies. R package version 51–4; 2019.
29.
go back to reference Jin JZaZ. nomogramFormula: Calculate Total Points and Probabilities for Nomogram. R package version 1.2.0.0. 2020. Jin JZaZ. nomogramFormula: Calculate Total Points and Probabilities for Nomogram. R package version 1.2.0.0. 2020.
33.
go back to reference Kolde R. pheatmap: Pretty Heatmaps. R package version 1.0.12. 2019. Kolde R. pheatmap: Pretty Heatmaps. R package version 1.0.12. 2019.
42.
go back to reference Gribouval O, Boyer O, Knebelmann B, Karras A, Dantal J, Fourrage C, et al. APOL1 risk genotype in European steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis patients of different African ancestries. Nephrol Dial Transplant. 2019;34(11):1885–93. https://doi.org/10.1093/ndt/gfy176.CrossRefPubMed Gribouval O, Boyer O, Knebelmann B, Karras A, Dantal J, Fourrage C, et al. APOL1 risk genotype in European steroid-resistant nephrotic syndrome and/or focal segmental glomerulosclerosis patients of different African ancestries. Nephrol Dial Transplant. 2019;34(11):1885–93. https://​doi.​org/​10.​1093/​ndt/​gfy176.CrossRefPubMed
Metadata
Title
Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis
Authors
Jianpeng Li
Jinlong Cao
Pan Li
Zhiqiang Yao
Ran Deng
Lijun Ying
Junqiang Tian
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08611-z

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine